70th Day Of Lockdown

Maharashtra70013301082362 Tamil Nadu2349513170187 Delhi208348746523 Gujarat17217107801063 Rajasthan91006213199 Uttar Pradesh83615030222 Madhya Pradesh82835003358 West Bengal57722306325 Bihar3945174123 Andhra Pradesh3676237464 Karnataka3408132852 Telangana2792149188 Jammu and Kashmir260194631 Haryana2356105521 Punjab2301200044 Odisha210412459 Assam14862854 Kerala132760811 Uttarakhand9592225 Jharkhand6612965 Chhatisgarh5481211 Tripura4231730 Himachal Pradesh3401186 Chandigarh2972144 Manipur83110 Puducherry79250 Goa73500 Nagaland4300 Meghalaya28121 Arunachal Pradesh2010 Mizoram110 Sikkim100
Lifestyle Health and Wellbeing 29 Jan 2018 Swiss drugmaker wins ...

Swiss drugmaker wins FDA's breakthrough therapy label for autism drug

REUTERS
Published Jan 29, 2018, 4:00 pm IST
Updated Jan 29, 2018, 4:00 pm IST
Autism spectrum disorder has no standard FDA-approved drugs for its core symptoms.
Swiss drugmaker wins FDA's breakthrough therapy label for autism drug. (Photo: Pixabay)
 Swiss drugmaker wins FDA's breakthrough therapy label for autism drug. (Photo: Pixabay)

ZURICH: Swiss drugmaker Roche said on Monday the U.S. Food and Drug Administration granted its breakthrough therapy designation for Balovaptan to treat autism spectrum disorder (ASD), potentially accelerating its development and approval.

Balovaptan, which may improve social interaction and communication in people with ASD, is being developed by Roche’s Swiss-based pRED research unit and has an expected filing date of after 2020, according to the company’s website.

 

Autism spectrum disorder has no standard FDA-approved drugs for its core symptoms such as social interaction difficulties, communication challenges and a tendency to engage in repetitive behaviors. Roche said Balovaptan has shown the potential to improve social interaction and communication in people with ASD.

“We look forward to working closely with the FDA in the hope that we can bring this medicine to these individuals as quickly as possible,” said Roche Chief Medical Officer Sandra Horning.

Roche’s pRED research and development unit has historically lagged the output of its California-based Genentech unit, the source of nearly all its biggest sellers.

Still, the Basel-based company has begun highlighting several pRED medicines, including Balovaptan, as among its top drug prospects.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT